|
Pancreatic Cancer Action Network: Posted on Saturday, November 10, 2012 3:59 PM
The Pancreatic Cancer Action Network is pleased to share the positive results of a pivotal clinical trial in the treatment of pancreatic cancer that were announced today by Celgene Corporation (Celgene). Celgene conducted a phase III clinical trial with the intent to show that the combination of its chemotherapy drug, ABRAXANE®, with gemcitabine would improve overall survival in patients with untreated, metastatic pancreatic adenocarcinoma when compared with gemcitabine alone. Treatment with gemcitabine alone has been the standard of care for pancreatic cancer. |
|
|
NCI: Posted on Thursday, November 08, 2012 12:06 AM
Use of PBSCs from related and unrelated donors has skyrocketed in the last decade, largely due to the preference of transplant doctors, explained Dr. |
|
|
NCI: Posted on Friday, October 19, 2012 4:39 PM
Nelfinavir, a drug used to treat people infected with HIV, appears to halt the growth of HER2-positive breast cancer cells. Researchers led by Dr. Joong Sup Shim of the Johns Hopkins School of Medicine showed that, in the laboratory, doses of nelfinavir used to safely treat people infected with HIV inhibited the growth of drug-resistant HER2-positive breast cancer cells. The study appeared October 5 in theJournal of the National Cancer Institute.
Although several drugs are approved to treat HER2-positive breast cancers, tumors often develop |
|
|
NCI: Posted on Friday, October 19, 2012 3:50 PM
An increase in the incidence of anal cancer among men in the United States during recent decades may have been driven in part by the HIV epidemic that occurred during the same period, a new study suggests. The results, published in the Journal of the National Cancer Institute on October 4, provide a framework for understanding the rising rates of anal cancer in men and could help guide efforts to prevent the disease.
|
|
|
NCI: Posted on Friday, October 19, 2012 3:36 PM
New results from three clinical trials highlight the evolving treatment options for women who have HER2-positive breast cancer. These cancers, which produce too much HER2 receptor protein, are a particularly aggressive form of the disease and account for approximately 20 percent of all breast cancer diagnoses.
In one trial, researchers showed that the investigational drug T-DM1 improved overall survival in women with advanced HER2-positive disease who had been previously treated with the HER2-targeted drug trastuzumab (Herceptin) and taxane chemotherapy. |
|
|
Memoirs of Cancer: Posted on Saturday, October 13, 2012 1:19 AM
The Charles and Tatisa Joiner Foundation Presents A COLORFUL JOURNEY 5th Year Celebration of Life Gala Saturday, October 13, 20125:30-11 p.m. Tinley Park Convention Center18451 Convention Center Drive Tinley Park, Il. 60477 Dinner, open bar, dancing. Tickets $75.00 Walk-ins welcome. The Joiner Foundation raises funds for cancer patients across the country with special concern for African Americans.
 The Joiner are featured on the cover of the new book "Memoirs of Cancer" by Dina Nwaokai-Beecham |
|
|
ACS: Posted on Friday, October 12, 2012 1:18 PM
A recent study by American Cancer Society grantee Annette E. Maxwell, DrPH, from the University of California, Los Angeles, found that small, community-based multi-component interventions significantly increased colon cancer screening among Filipino Americans.
|
|
|
Memoirs of Cancer/ ACS: Posted on Friday, October 12, 2012 12:38 PM
New program developed called Esperanza y Vida (Hope and Life), is created by Deborah Erwin, PhD. This is a community-based program designed to increase breast and cervical cancer screenings among Latina women. Read more on our new page Recent Developments In Cancer Research Here.
To learn more on breast cancer click here. |
|
|
NCI/MEMOIRS OF CANCER: Posted on Thursday, October 11, 2012 12:36 PM
 Using a combination of analytical tools, investigators with The Cancer Genome Atlas(TCGA) Research Network have completed a molecular study of breast tumors from 825 women. The results, recently reported in Nature, confirm the existence of four major subtypes of breast cancer and add new details about the biological changes underlying these diseases.The researchers used up to six different technologies to characterize subsets of the tumors. In addition to sequencing DNA and |
|
|
NCI: Posted on Thursday, October 11, 2012 12:22 PM
|
